搜尋
Valneva SE
VALN添加自選
5.225USD
+0.135+2.65%
收盤 07/02, 13:00（美東）報價延遲15分鐘
453.93M總市值
虧損本益比TTM
關於 Valneva SE 公司
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE簡介
公司代碼VALN
公司名稱Valneva SE
上市日期Jun 28, 2007
CEOLingelbach (Thomas)
員工數量- -
證券類型Depository Receipt
年結日Jun 28
公司地址6, Rue Alain Bombard
城市SAINT-HERBLAIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家France
郵編44800
電話33228073710
網址https://valneva.com/
公司代碼VALN
上市日期Jun 28, 2007
CEOLingelbach (Thomas)
Valneva SE公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
常見問題
Valneva SE的前五大股東是誰？
Valneva SE的前五大股東如下：Mr. Franck Grimaud
有多少機構持有Valneva SE(VALN)的股份？
截至2026Q1，共有36家機構持有Valneva SE的股份，合計持有的股份價值約為5.21M，占公司總股份的5.50% 。與2025Q4相比，機構持股有所增加，增幅為-309162.00。
哪個業務部門對Valneva SE的收入貢獻最大？
在2026Q1，IXIARO業務部門對Valneva SE的收入貢獻最大，創收98.42M，占總收入的56.35% 。